{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:15Z","timestamp":1792979895869,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijantimicag.2025.107634","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:22:24Z","timestamp":1758946944000},"page":"107634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of tenofovir alafenamide fumarate\u2013based therapy compared with tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-6434","authenticated-orcid":false,"given":"Elizabeth","family":"Chappell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Doerholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Ene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Goetghebuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sannie Brit","family":"Nordly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Marczynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Naver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Noguera-Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Paioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Spoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Alvarez","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Bamford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge G\u00f3mez","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio F","family":"Medina-Claros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Soeria-Atmadja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Crichton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intira Jeannie","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Judd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107634_bib0001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0003","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv."},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0004","unstructured":"Penta HIV Guidelines Writing Group on behalf of Penta. PENTA HIV first and second line antiretroviral treatment guidelines 2019. Available at https:\/\/penta-id.org\/wp-content\/uploads\/2025\/10\/PENTA_HIV-1st-2nd-Line-ARV-Treatment-Guidelines-2019_v1.0_20191109_ARCHIVED.pdf"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0005","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0006","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14\u200a894 patients across 14 trials","volume":"34","author":"Pilkington","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0008","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000002541","article-title":"Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV","volume":"34","author":"Lacey","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0009","doi-asserted-by":"crossref","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides","volume":"9","author":"Mallon","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S2352-4642(21)00165-6","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2\/3 trial","volume":"5","author":"Gaur","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0011","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1016\/S2352-3018(16)30121-7","article-title":"Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial","volume":"3","author":"Gaur","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2352-4642(17)30009-3","article-title":"Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial","volume":"1","author":"Natukunda","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26037","article-title":"Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review","volume":"26","author":"O'Rourke","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hiv.13562","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in paediatrics: real-life experience from a French cohort (2019\u20132023)","volume":"25","author":"Frange","year":"2024","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0015","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJMoa2404597","article-title":"Second-line antiretroviral therapy for children living with HIV in Africa","volume":"392","author":"Musiime","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(15)00225-8","article-title":"Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis","volume":"3","author":"Jesson","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(02)07874-1","article-title":"Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0018","unstructured":"US Department of Health Human Services. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.1.[July 2017]. 2017. Available at: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0019","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0021","series-title":"WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children","year":"2007"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0022","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0023","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/hiv.70070","article-title":"Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe","volume":"26","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0024","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0025","first-page":"407","article-title":"HIV and cardiovascular disease: from insights to interventions","volume":"29","author":"Feinstein","year":"2021","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0026","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11904-021-00574-x","article-title":"Cardiometabolic complications in youth with perinatally acquired HIV in the era of antiretroviral therapy","volume":"18","author":"Dirajlal-Fargo","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0027","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/COH.0000000000000938","article-title":"Aging of adult lifetime survivors with perinatal HIV","volume":"20","author":"Mallik","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0028","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/biomedicines9091078","article-title":"Treatment of dyslipidaemia in children","volume":"9","author":"Fiorentino","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijantimicag.2025.107634_bib0029","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792500189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792500189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:11:51Z","timestamp":1775517111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792500189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S092485792500189X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107634","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of tenofovir alafenamide fumarate\u2013based therapy compared with tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107634"}}